secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092270
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027
----------------------------------------------------------------------

- Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.
- Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).
- R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.
- Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.
- PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/0000950170-24-092270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer